Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|June 3, 2015
Sartorius Opens New York Demonstration Lab
Author(s)Pharmaceutical Technology Editors
A new demonstration facility in New York gives Sartorius’ customers hands-on access to bioprocessing systems and lab instruments.
Sartorius has opened its first North American demonstration laboratory in Bohemia, NY to provide customers with access to the company’s upstream and downstream processing systems and laboratory products. The laboratory, part of the company’s new 40,000-sq-ft facility, features hands-on demonstration stations, as well as classroom learning space.
The Long Island-based Sartorius Application Center is modeled after similar application centers in China and Germany. In the FlexLab, customer can view FlexAct systems, Sartocheck bag testers, and TAP Biosystems equipment. Laboratory products on display include scales, balances, and liquid handling systems. In addition, an R&D section showed developments in bioreactors and freeze/thaw equipment.
At a grand opening event on June 2, Sartorius hosted customers, employees, the media, and local government officials for a ribbon-cutting ceremony and facility tours with introductions provided by Mary Lavin, the company’s president for North America.
Source:
Related to this article
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.